Dan Churach
Dansplaining Dan's Current Projects
I'm always getting ideas for storylines! Of course, most of the time, an idea dies at the inception stage, but once in a while, the inspiration grows into a full-fledged plot for a novel. Here is the latest work I'm doing on the next Churachian novel.
Cheers ,
Dan
Dansplaining CLOUDS For release after KAIROS
Caution: NOT a real nanobot!
CLOUDS is becoming an ongoing project that I am determined to complete sometime in early 2023. Surprisingly, I'm already a quarter-to-a-third of the way into writing this novel, but was distracted by first by SOLASTALGIA and wrote that story, the second book in the Ancestor Trilogy. I then picked up writing CLOUDS again the last few months of 2021 before I became distracted with inspirations pushing me to write KAIROS (see Dansplaining the Ancestor Trilogy)). That said, I am getting back to CLOUDS this spring (September, October, November 2022) and have every intention of finishing up this time. CLOUDS is only a working title, but the way the story is unfolding, I think I might stick with that for the final title this technothriller. I can at least give you some insight as to what I'm working on.
GenoBotics is a new start-up company developed by a couple of Western Australia researchers attempting to use the laws of physics integrated with biomolecular research to develop robotic devices that are as small as molecules. These nanobots can be used medically to deliver drugs to precisely the right place within an individual’s body to help remedy disease. The best example of this technique is in the early stages of development today and will be used to allow oncologists to better treat cancer patients.
Many modern pharmaceuticals intended to fight cancer are designed to interfere inside the targeted malignant cells and cause harm to their DNA. Naturally, the trick is to confine their therapeutic behaviour of the chemo drugs specifically to only the diseased cells making up the tumour. Enter nanorobotics and the guided attack on only unhealthy cells. Enough of the science for now.
GenoBotics shows much promise, but as often is the case with Australian research, the lack of seed money drives GenoBotics into a merger with Gunn Capital, a large California-based company keen on backing this cutting-edge research.
Now that KAIROS is done and dusted, I'm back to working on CLOUDS. So, that's where things are in September 2022. I'll keep you posted as I get closer to finishing up this one.
Nanobots at work in a bloodstream... Again, don't take these images too seriously. They do give at least some idea of what GenoBotics is all about - manipulating VERY small bits within the human body..